Fulcrum Therapeutics Inc FULC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?
-
Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders?
-
Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders?
-
Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders?
-
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
-
Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders?
-
Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders?
-
Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders?
Trading Information
- Previous Close Price
- $3.64
- Day Range
- $3.63–3.74
- 52-Week Range
- $2.83–15.74
- Bid/Ask
- $3.64 / $3.74
- Shares Outstanding
- 76.38M
- Market Cap
- $282.61M
- Volume/Avg
- 333 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 55
- Website
- https://www.fulcrumtx.com
Valuation
|
Metric
|
FULC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.91 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
FULC
Financial Strength
|
Metric
|
FULC
|
|---|---|
Quick Ratio | 31.16 |
Current Ratio | 31.35 |
Interest Coverage | — |
Quick Ratio
FULC
Profitability
|
Metric
|
FULC
|
|---|---|
Return on Assets (Normalized) | −20.95% |
Return on Equity (Normalized) | −22.07% |
Return on Invested Capital (Normalized) | −21.57% |
Return on Assets
FULC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?^j>b>@ | LOCK|^wc^ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y@Vcrw | LOCK|?>P# | $84B | |||
| Moderna Inc
MRNA
| LOCK|FgDDB<< | LOCK|r%k | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#j>#&j? | LOCK|$^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@C^<Zw | LOCK|@YV | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!N&>ZWV | LOCK|&?r$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!%#Ll&$ | LOCK|nYk! | $29B | |||
| Incyte Corp
INCY
| LOCK|DJPRW@^ | LOCK|PP? | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|xgXy?>P | LOCK|%D? | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|d$>KCg& | LOCK|?^ | $14B |
United States